Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349602 | 0.85 | LIPE (1.00) | LIPE | |
| SCHEMBL350214 | 0.84 | LIPE (1.00) | LIPE | |
| SCHEMBL348777 | 0.82 | LIPE (1.00) | LIPE | |
| SCHEMBL347868 | 0.80 | LIPE (1.00) | LIPE | |
| SCHEMBL349222 | 0.79 | LIPE (0.75) | LIPE | |
| SCHEMBL349221 | 0.79 | LIPE (0.75) | LIPE | |
| SCHEMBL336543 | 0.76 | LIPE (0.61) | LIPE | |
| SCHEMBL350200 | 0.75 | LIPE (1.00) | LIPE | |
| SCHEMBL3741527 | 0.74 | LIPE (0.58) | LIPE | |
| SCHEMBL348448 | 0.74 | LIPE (1.00) | LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470843-B2 | Azacyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-20120015970-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | claimed |
| US-8470843-B2 | Azacyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470843-B2 | Azacyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470843-B2 | Azacyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| EP-2593454-A1 | NEW AZACYCLIC COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20120015970-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015970-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015970-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007367-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015970-A1 | NEW AZACYCLIC COMPOUNDS | AZI2, CDKN1A, TOP2B | LIPE 4875/4885EPHX2 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.